MediGuard: Medication Safety Dataset
- MediGuard is a dataset and benchmarking framework for classifying consumer medication questions as critical or general using clinical risk factors.
- It leverages manual annotations from a NIH-derived corpus and compares models like BioBERT, BlueBERT, and GPT-4.1 alongside classical classifiers.
- The MediGuard label also underpins design blueprints for pill recognition, RFID-based event sensing, and multi-agent AI safety, distinct from similarly named frameworks.
to=arxiv_search 天天中彩票上json code {"query":"MediGuard medication-related questions arXiv (Goncharok et al., 15 Sep 2025)", "max_results": 5} MediGuard most directly denotes a publicly released dataset and benchmark for identifying clinically “critical” medication-related questions in consumer health content, with the stated goal of supporting early warning and real-time triage in digital health spaces (Goncharok et al., 15 Sep 2025). Within the broader medication-safety literature supplied here, the same label is also used for several design-level syntheses: a pill-recognition subsystem built on MEDISEG (Chu et al., 11 Mar 2026), a cyber-physical medication-administration architecture grounded in MECL-RFID (Ma et al., 2018), a continuous monitoring and emergency-response extension derived from Medisûr (Chatterjee et al., 2019), and a safety blueprint for medical LLM multi-agent systems grounded in MedSentry (Chen et al., 27 May 2025). A similarly named framework, MedGuards, is distinct; its paper explicitly states that “MediGuard” is a misspelling rather than an alternate name (Ma et al., 24 Jun 2026).
1. Nomenclature and conceptual range
In the most specific and published sense, MediGuard is “a publicly released dataset and benchmark for detecting critical, medication-related questions in consumer health content,” and it is “primarily a dataset plus an accompanying benchmarking framework, not an end-to-end deployed system nor a single model suite” (Goncharok et al., 15 Sep 2025). The task is binary classification of patient-authored medication questions into “critical” versus “general,” grounded in clinical risk factors.
The supplied literature also applies the same label to broader safety architectures. One synthesis uses MediGuard for a pill-recognition subsystem trained and evaluated with MEDISEG; another uses it for a medication-administration monitoring system based on Multi-Element ChipLess RFID sensing; another adapts Medisûr into a more capable continuous monitoring platform; and another uses MediGuard as a design and defense blueprint for medical LLM multi-agent systems (Chu et al., 11 Mar 2026, Ma et al., 2018, Chatterjee et al., 2019, Chen et al., 27 May 2025). This suggests that, across recent work, MediGuard functions less as a single standardized artifact than as a recurrent design name for medication-safety and medical-safety infrastructures.
The strongest source of terminological confusion is MedGuards. That framework treats medical error detection and correction as a multi-agent in-context learning task, but the paper states unambiguously that “The term ‘MediGuard’ does not appear in the paper and is not an alternate name; it is a mis-spelling” (Ma et al., 24 Jun 2026). For technical disambiguation, MediGuard and MedGuards should therefore be treated as separate entries.
2. MediGuard as a medication-question risk dataset
The MediGuard dataset in (Goncharok et al., 15 Sep 2025) was annotated from the MedInfo2019-QA-Medications dataset, itself described as closely associated with MEDIQA 2019/MedQuAD and comprising 47,457 question–answer pairs from 12 authoritative U.S. NIH websites, including MedlinePlus and Cancer.gov. From this NIH-based corpus, 650 medication-related questions were manually labeled for risk. The label space is binary: “critical” and “general.”
| Aspect | Reported specification |
|---|---|
| Source corpus | 47,457 NIH question–answer pairs |
| Labeled subset | 650 medication-related questions |
| Labels | “critical” and “general” |
| Class balance | “only around 100” critical |
| Split | 80/20 stratified train–test |
The annotation criteria emphasize overdose, contraindicated combinations, harmful drug interactions, and urgent or life-threatening symptoms (Goncharok et al., 15 Sep 2025). The paper gives concrete examples: “Is it safe to take ibuprofen while on blood thinners?” and “What happens if I accidentally take 50mg of lisinopril twice?” are labeled Critical, whereas “Can I split my metformin pill to reduce the dose?” and “Is it okay to drink grapefruit juice with my medication?” are labeled General. The paper explicitly notes that the grapefruit-juice example indicates conservative annotation unless explicit danger is implied.
The annotation process is described as manual and based on clinical risk factors, but detailed guidelines, adjudication procedures, and inter-annotator agreement are not reported (Goncharok et al., 15 Sep 2025). No kappa values are provided. The class distribution is highly imbalanced, with an approximate critical proportion of about 15%, and the paper does not report average or median question length, vocabulary size, or entity prevalence. These omissions matter methodologically because they constrain reproducibility analyses of annotation consistency and dataset difficulty.
3. Benchmark design, representations, and reported performance
For traditional models, the paper reports preprocessing by removing irrelevant characters, stop words, and formatting artifacts, followed by word-level tokenization, TF-IDF representation, and Truncated SVD/LSA for dimensionality reduction (Goncharok et al., 15 Sep 2025). The stated TF-IDF form is
A distinctive hand-engineered feature is “Critical Similarity,” defined operationally as the maximum cosine similarity between a question’s TF-IDF vector and the vectors of critical training examples:
The benchmark compares classical classifiers with fine-tuned encoders and a prompted decoder. The reported fine-tuned encoder models are BERT, BioBERT, and BlueBERT; the prompted decoder is GPT-4.1 used with few-shot prompting and no fine-tuning (Goncharok et al., 15 Sep 2025). The paper states that it evaluates “six traditional classifiers,” but Table 2 reports five classical results; any additional classical model is not shown in the table.
| Model | Accuracy | F1 |
|---|---|---|
| BioBERT | 0.92 | 0.90 |
| BlueBERT | 0.91 | 0.90 |
| GPT-4.1 | 0.87 | 0.85 |
| Linear SVM | 0.84 | 0.80 |
| SGD Logistic (L2) | 0.79 | 0.79 |
| Gradient Boosting | 0.79 | 0.77 |
| Logistic Regression | 0.76 | 0.77 |
| Random Forest | 0.68 | 0.70 |
These results position BioBERT and BlueBERT as the strongest reported models, with the best classical baseline being Linear SVM at Accuracy 0.84 and F1 0.80 (Goncharok et al., 15 Sep 2025). GPT-4.1 is competitive overall but materially weaker than the fine-tuned biomedical encoders. For GPT-4.1, the class-wise metrics reported in Figure 1 are strongly asymmetric: General class Precision 0.93, Recall 0.91, F1 0.92; Critical class Precision 0.68, Recall 0.64, F1 0.60. The minority “critical” class therefore remains the difficult operating regime.
The evaluation uses an 80/20 stratified train–test split, with 5-fold cross-validation on the training set for classical models (Goncharok et al., 15 Sep 2025). Accuracy and F1 are reported for all models, while class-wise Precision/Recall/F1 are reported for GPT-4.1. Macro/micro averaging, ROC-AUC, PR-AUC, calibration, and statistical significance testing are not reported. A plausible implication is that downstream deployment would need additional threshold calibration and cost-sensitive evaluation if critical-case recall were operationally prioritized.
4. MediGuard as visual pill recognition and dosette verification
A separate synthesis leverages MEDISEG to build and evaluate a robust pill-recognition subsystem for medication safety under the MediGuard label (Chu et al., 11 Mar 2026). MEDISEG contains two subsets: MEDISEG (3-Pills), with 3 visually confusable pill classes across 2,333 images, and MEDISEG (32-Pills), with 32 pill classes across 8,262 images. It includes single-pill frames, multi-pill compositions, cluttered dosette boxes, overlapping and partially occluded pills, varied lighting, top-down and side views, and full-field spatial distributions rather than centrally biased framing.
The annotations are COCO-style instance segmentation annotations with polygon masks and bounding boxes, with 32 distinct pill classes in the comprehensive subset and 3 classes in the focused subset chosen for fine-grained confusion (Chu et al., 11 Mar 2026). The dataset does not annotate textual imprints or explicit shape/color attributes per instance, but metadata.csv provides regulatory descriptors including registration ID, product name and strength, certificate holder details, active ingredient(s), sale requirement, registration date, and a URL to official product records. Images were reviewed by both the initial annotator and a secondary reviewer, and dosette images were cropped to pill slots, padded, and resized to a uniform 640×640 resolution.
YOLOv8 and YOLOv9 were trained on MEDISEG using a 70% training, 20% validation, and 10% test hold-out protocol (Chu et al., 11 Mar 2026). The reported validation performance is [email protected] of 99.5% on the 3-Pills subset and 80.1% on the 32-Pills subset. On 3-Pills, YOLOv9 training curves reached [email protected] of approximately 0.965, versus approximately 0.950 for YOLOv8; on 32-Pills, YOLOv9 at epoch 20 reached [email protected] of approximately 0.801 and [email protected] of approximately 0.684. The paper further reports few-shot transfer gains on an overlap-only subset: foreground classification accuracy was 0.406 versus 0.131 at 1-shot, 0.625 versus 0.372 at 5-shot, and 0.740 versus 0.558 at 10-shot for MEDISEG-initialized versus CURE-initialized models.
Operationally, the MediGuard-style pipeline described in the synthesis uses 640×640 padding/resizing, class-aware NMS, mapping of detections to metadata.csv, and optional compartment cropping when full dosette trays are captured (Chu et al., 11 Mar 2026). It recommends YOLOv9 as the primary detector, threshold calibration per class on the MEDISEG validation set, segmentation-capable models such as YOLOv8-seg or Mask R-CNN for tightly overlapping pills, confidence calibration by Platt scaling or temperature scaling, and human-in-the-loop review for low-confidence or high-entropy cases. In pharmacy tray filling and bedside administration, the intended workflow is to compare the predicted pill set against the prescription or scheduled regimen and flag mismatches or missing pills.
5. MediGuard as cyber-physical event sensing and continuous monitoring
Another MediGuard formulation is grounded in “Demonstration Paper: Wirelessly Sensing Medication Administration: Cyber-Physical Event Detection and Notification Utilizing Multi-Element Chipless RFID” (Ma et al., 2018). In that design, medication safety is coupled to the physical act of opening a tagged pill container. Multi-Element ChipLess RFID tags comprise passive resonant metallic patterns on the bottle body and lid; opening and closing alter capacitive or inductive coupling, producing distinct event signatures in the backscatter spectrum. The prototype operates in the 1.2–1.6 GHz band with a USRP N210 SDR. The reported event-dependent notches are a primary notch at approximately 1.6 GHz in the closed state, narrower in width, and a primary notch at approximately 1.2 GHz in the open state, wider in width.
The prototype implements a Pattern Recognition Approach using amplitude-only features and Euclidean similarity to open/closed templates (Ma et al., 2018). Under AWGN-only conditions, both PRA and the Matrix Pencil Method achieve near-zero error above SNR approximately 18.5 dB, but with added uniform phase noise of 1 degree, MPM’s normalized decoding error exceeds 60% even at high SNR, whereas PRA remains robust because it uses amplitude-only features. MediGuard, in this formulation, binds timestamped opening events to bottle identity and location, then queries orders and policy rules to verify the “5 rights”: right drug, dose, patient, form, and route.
A further synthesis adapts the microcontroller-based Medisûr system into a MediGuard-style continuous monitoring and emergency-response platform (Chatterjee et al., 2019). The underlying prototype uses an ATmega328-based wearable with an LM35 analog temperature sensor, an M212 pulse sensor, an emergency button, and a 434 MHz RF transmitter. A receiving kit built around an Arduino Uno decrypts incoming AES-256 payloads, attaches NEO-6 GPS location, uses a SIM300 GSM/GPRS modem for SMS and HTTP GET, and forwards data to a Microsoft Azure VM with Microsoft SQL Server and a WCF service. The server maintains currentPatientData, updates it every minute, and aggregates patientHistry every 6 hours.
The implemented alert logic is simple and threshold-based: emergency button value 1 triggers immediate SMS; temperature greater than 99°F triggers SOS SMS; pulse rate less than 40 bpm triggers SOS SMS (Chatterjee et al., 2019). Example plaintext payloads take the form “SXCMS:1,98,77,” and the wearable-to-receiver link uses AES-256 with a device-specific key such as “MS001,” while the receiver-to-server link uses AES-256 with a global key “MedS.” The paper identifies the global key as a security weakness and recommends stronger approaches. Proposed MediGuard extensions include replacing 434 MHz RF with BLE or Zigbee, using LTE-M/NB-IoT and MQTT over TLS, upgrading to digital temperature and dual-wavelength PPG sensors, adding SpO2 and fall detection, and enforcing escalation logic when alerts are unacknowledged.
6. Relation to multi-agent medical AI safety
The nearest homophone in the literature is MedGuards, a distinct framework for medical error detection and correction in text (Ma et al., 24 Jun 2026). MedGuards decomposes the task into detector, localizer, and corrector agents, uses Chain-of-Thought with structured tags such as >, <confidence>, and <result>, and resolves disagreements through confidence-guided arbitration. It also introduces the Keyword-Prioritized Correction Score:
with used by default. On MEDEC, MedGuards with a Doubao backbone achieved Detection 0.770, Localization 0.716, ROUGE-1 0.724, BERTScore 0.731, and BLEURT 0.695, and the paper reports statistically significant improvements across multilingual MedErrBench subsets. Despite the name similarity, this framework is not MediGuard.
Separately, a MediGuard blueprint is synthesized from MedSentry, a benchmark of 5,000 adversarial medical prompts spanning 25 threat categories and 100 subthemes for evaluating medical LLM multi-agent systems (Chen et al., 27 May 2025). In that formulation, MediGuard is a defended MAS architecture evaluated by Length-Controlled Score (LCS) and Raw Score (RS). The four topologies analyzed are Layers, SharedPool, Centralized, and Decentralized. Under attack by a single dark-personality agent, the mean baseline-to-attack safety drops averaged over GPT-4o and Claude-3.7 subsets are smallest for Decentralized, with LCS drop 2.6% and RS drop 2.7%, and largest for SharedPool, with LCS drop 8.7% and RS drop 9.6%. A topology-agnostic Enforcement Agent performing psychometric screening, behavioral verification, and topology-aware isolation restores safety close to baseline across all topologies.
The design guidance derived from MedSentry favors a Decentralized topology as the primary choice for safety-critical settings, avoids SharedPool as the sole architecture in high-risk contexts, and recommends immediate isolation, purge-on-flag policies, time-aware audits, and signed messages with source verification (Chen et al., 27 May 2025). This line of work extends the MediGuard label from medication-specific safety into general medical AI safety engineering, but it does so through a blueprint grounded in another benchmark rather than through a standalone published system named MediGuard.
Across these usages, MediGuard consistently denotes safety-oriented mediation between raw clinical or patient-generated signals and an intervention workflow. The signals differ—consumer questions, pill images, bottle-opening events, wearable vitals, or multi-agent dialogue traces—but the shared objective is to surface risk states early enough to support verification, escalation, and human oversight. The main limitations are correspondingly heterogeneous: the medication-question dataset lacks reported inter-annotator agreement and is drawn from NIH content rather than informal forums (Goncharok et al., 15 Sep 2025); MEDISEG covers 32 pill classes rather than the full pharmacopeia (Chu et al., 11 Mar 2026); MECL-RFID range and orientation performance are not quantified (Ma et al., 2018); the Medisûr-derived design uses a global encryption key on the server uplink (Chatterjee et al., 2019); and multi-agent LLM guardrails incur nontrivial token and latency overheads while remaining vulnerable to some forms of adversarial contamination (Ma et al., 24 Jun 2026, Chen et al., 27 May 2025).